Korro Bio, Inc. (KRRO)
NasdaqCM · USD · Healthcare · Biotechnology
$12.02 (+0.33%) as of
Key statistics
- Market cap
- 177.00M
- Forward P/E
- -2.72
- EPS (TTM)
- -9.88
- Dividend yield
- 0.00%
- 52-week range
- 5.20 – 42.70
- Beta
- 2.36
- Revenue (TTM)
- 2.38M
- Profit margin
- 0.00%
- Analyst target
- $20.20
- Volume
- 179.94k
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA, United States
- Employees
- 57
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.